Destiny Pharma plc
(“Destiny Pharma” or “the Company”)
Destiny Pharma to present at the Inv€$tival Showcase in partnership with Jefferies
Brighton, United Kingdom – 15 November 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti‐microbial drugs that address clear commercial opportunities and also address the global problem of anti‐microbial resistance (AMR), announces that Neil Clark, Chief Executive Officer of Destiny Pharma, will present at the Inv€$tival Showcase, in partnership with Jefferies, on 19 November 2019 in London, UK.
About Inv€$tival Showcase
Returning for its fourth year, LSX’s Inv€$tival Showcase continues and expands upon its exclusive partnership with global investment bank Jefferies, with the showcase co-located with the Jefferies 2019 London Healthcare Conference.
The Inv€$tival Showcase directly connects life sciences corporates to global capital and offers the opportunity for a greater proportion of private and smaller cap public companies to be a part of the biggest week in European life sciences investment. It provides the opportunity to pitch, profile and connect with investment partners brought together in London by both LSX and Jefferies.
Over the last three years, Inv€$tival Showcase has welcomed numerous companies across all areas of biotech, medtech and healthtech. Their investor network is particularly interested in innovations in oncology, neurology, infectious diseases, immunology, cardiovascular, musculoskeletal, respiratory and cardiometabolic.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
Simon Conway / Victoria Foster Mitchell
+44 (0) 20 3727 1000
finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development and commercialisation of novel medicines from its XF Platform that represent a new approach to the treatment of infectious disease. The company’s lead programme is undergoing a Phase 2b clinical trial and is targeting the prevention of post‐surgical hospital infections including MRSA. The XF drug candidates are being developed for the prevention and treatment of life‐threatening infections caused by antibiotic‐resistant bacteria, often referred to as “superbugs”. Tackling anti‐microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com